Thymosin Beta-4

Thymosin beta 4 is a small, abundant, naturally occurring regenerative peptide found in body fluids and inside cells. ^[1] It is a highly conserved 43-amino-acid peptide encoded by the X-linked TMSB4X gene and is the predominant beta-thymosin in mammalian cells. ^[2] In 1990 it was recognized that thymosin beta 4 sequesters G-actin, and beta-thymosins are the main intracellular G-actin-sequestering peptides in most vertebrate cells. ^[3] It is marketed direct to patients in sports medicine as an unapproved peptide, sold as Tβ4 and as the fragment TB-500, operating largely outside regulatory oversight. ^[4]

Thymosin beta 4 is an actin-binding protein that inhibits the polymerization of G-actin into F-actin, controlling cell morphogenesis and motility by regulating actin cytoskeleton dynamics. ^{[5] [6]} It has multiple biological activities including down-regulation of inflammatory chemokines and cytokines, and promotion of cell migration, blood vessel formation, cell survival, and stem cell maturation. ^[7] Its N-terminal metabolite N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is produced endogenously from the peptide and shares antifibrotic and anti-inflammatory properties and stimulates angiogenesis. ^{[8] [9]}

Thymosin beta 4 increases the rate of dermal healing in various preclinical animal models including diabetic and aged animals, and accelerated repair in phase 2 trials in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. ^[1] In preclinical models of cardiac ischemic injury, thymosin beta 4 reduces infarct volume and preserves cardiac function through antifibrotic and proangiogenic activities. ^[10] For the eye, thymosin beta 4 has been studied in phase 3 clinical trials to treat dry eye and neurotrophic keratopathy. ^[11] Despite very promising experimental evidence in cardiac healing, there are no data available from a clinical trial supporting the use of thymosin beta 4 or Ac-SDKP to heal the myocardium after infarction in patients. ^[9] As an anti-aging regenerative candidate its supporting data derive from mouse embryo expression studies and systemic injection in animals, and the authors frame reversing aging with the peptide as a hypothesis requiring further discovery. ^[12]

In dermal healing studies thymosin beta 4 is described as safe and well tolerated. ^[1] For many unapproved peptides such as thymosin beta 4, favorable tissue-repair outcomes appear in animal models but rigorous human safety data are scarce and there is potential for serious harm to patients. ^[4] In thyroid and endocrine contexts, available data on thymosin beta 4 consist primarily of preclinical investigations and early exploratory clinical reports rather than large randomized trials, and clinical use remains largely investigational. ^[13] Key remaining challenges include validating efficacy in additional clinically relevant models, overcoming peptide instability, and completing comprehensive safety assessments. ^[2]